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The nutrient- and growth factor-responsive kinase
mTOR complex 1 (mTORC1) regulates many pro-
cesses that control growth, including protein
synthesis, autophagy, and lipogenesis. Through
unknown mechanisms, mTORC1 promotes the func-
tion of SREBP, a master regulator of lipo- and sterol-
genic gene transcription. Here, we demonstrate that
mTORC1 regulates SREBP by controlling the nuclear
entry of lipin 1, a phosphatidic acid phosphatase.
Dephosphorylated, nuclear, catalytically active lipin
1 promotes nuclear remodeling and mediates the
effects of mTORC1 on SREBP target gene, SREBP
promoter activity, and nuclear SREBP protein abun-
dance. Inhibition of mTORC1 in the liver significantly
impairs SREBP function and makes mice resistant,
in a lipin 1-dependent fashion, to thehepatic steatosis
and hypercholesterolemia induced by a high-fat and
-cholesterol diet. These findings establish lipin 1 as
a key component of the mTORC1-SREBP pathway.INTRODUCTION
The mechanistic target of rapamycin (mTOR) is an evolutionarily
conserved serine/threonine kinase that has an essential role in
cell growth (Wullschleger et al., 2006). Genetic and biochemical
studies into the mechanism of action of rapamycin, which has
emerged as a valuable immunosuppressive and anticancer
drug (Abraham and Eng, 2008), led to the discovery of TOR as
its intracellular target (Brown et al., 1994; Chiu et al., 1994;
Heitman et al., 1991; Sabatini et al., 1994).
Rapamycin was initially noted for its antifungal activity as it
potently inhibited diverse amino acid, nucleic acid, and lipid-
utilizing metabolic processes (Singh et al., 1979). Since the iden-408 Cell 146, 408–420, August 5, 2011 ª2011 Elsevier Inc.tification of TOR, it has become increasingly appreciated that its
kinase activity is critical to several growth processes, including
protein synthesis. The effects of mTORC1 in translation are
thought to be controlled through rapamycin-sensitive phosphor-
ylation of its substrates, S6 kinase 1 (S6K1) and eIF4E-binding
protein 1 (4E-BP1) (Brown et al., 1995; Brunn et al., 1997; Hara
et al., 2002; Kim et al., 2002). Recently, the role of mTORC1 in
regulating translation was recast by the finding that rapamycin,
which allosterically partially inhibits mTOR kinase activity (Brown
et al., 1995), does not inhibit 4E-BP1 phosphorylation equally
well in all cell contexts despite invariantly promoting S6K1
dephosphorylation (Choo et al., 2008; Feldman et al., 2009;
Thoreen et al., 2009). On the other hand, catalytic site ATP-
competitive mTOR inhibitors, such as Torin1, suppress both
S6K1 and 4E-BP1 phosphorylation regardless of cell context
(Liu et al., 2010; Thoreen et al., 2009). In addition to translation,
catalytic site mTOR inhibitors, also potently regulate other
known outputs of mTORC1 signaling, such as autophagy and
proliferation, to a greater degree than rapamycin does (Dowling
et al., 2010; Feldman et al., 2009; Thoreen et al., 2009). These
results suggest that in viewing rapamycin as a complete
mTORC1 inhibitor, other mTORC1-dependent phenotypes
might have eluded detection.
The mTOR pathway regulates several anabolic and catabolic
pathways at the mRNA expression level (Du¨vel et al., 2010;
Porstmann et al., 2008). Critical to the regulation of fatty acid
and cholesterol biosynthetic gene expression is the SREBP
family of transcription factors (Horton et al., 2002). The SREBP
family is comprised of three isoforms: SREBP-1a, SREBP-1c,
and SREBP-2 (hereafter collectively referred to as SREBP unless
stated otherwise; SREBP-1a and SREBP-1c are encoded by the
same gene, SREBP-1, and differ in their first exon; SREBP-2 is
a distinct gene) (Horton et al., 2002). Studies by Brown, Gold-
stein, and colleagues have elucidated key parts of the mecha-
nism by which cholesterol sensing is coupled to the activity of
SREBP (Brown and Goldstein, 2009). Previous work shows
that mTORC1 positively regulates the activity of SREBP-1 (Du¨vel
Figure 1. mTORC1 Regulates Nuclear Eccentricity in a Rapamycin-Resistant Manner
(A) NIH 3T3 cells treated with 100 nM rapamycin, 250 nM Torin1, or vehicle for 12 hr were analyzed by immunoblotting for the phosphorylation states and levels of
the indicated proteins.
(B) NIH 3T3 cells treated with 100 nM rapamycin, 250 nM Torin1, or vehicle for 12 hr were processed in an immunofluorescence assay to detect lamin A (green),
costained with DAPI for DNA content (blue), and imaged. Illustrative nuclei for each condition are shown.
(C) Explanation of eccentricity. The eccentricity of an elliptical object is a measure of how much the shape of the ellipse deviates from being circular. Defined
mathematically, eccentricity = 1–2/((a/p) + 1), where a is the radius at apopasis, i.e., the farthest distance from the edge of the ellipse to its center, and p is the
radius at periapsis, i.e., the closest distance to ellipse center. The eccentricity of an ellipse is necessarily between 0 and 1; a circle has an eccentricity of 0. As the
eccentricity tends to 1, the ellipse becomes more elongated, and the ratio of a/p tends to infinity.
(D) Images processed in (B) were analyzed for nuclear eccentricity based on lamin A immunofluorescence by image analysis software (Carpenter et al., 2006).
Nuclear eccentricity distributions of rapamycin- and Torin1-treated cells were overlaid with those from corresponding vehicle-treated cells. Mean eccentricity
values for three independent fields for each condition (>500 cells total) are as follows: DMSO (black) 0.630; rapamycin (gray) 0.628; Torin1 (red) 0.704.
(E) Immunoblot analysis of TSC2 and raptor protein levels in p53/ mouse embryonic fibroblasts (MEFs) with RNAi-mediated knockdown of a control protein,
TSC2, or raptor.
(F) p53/ MEFs with knockdown of TSC2, raptor, or a control protein were analyzed as in (D). Mean eccentricity values for three independent fields for each
condition (>500 cells total) are as follows: shGFP (black) 0.660; shTSC2_1 (green) 0.622; shraptor_1 (red) 0.705.
(G) Immunoblot analysis of T37/T46 4E-BP1 phosphorylation in NIH 3T3 cells deprived of serum, serum and glucose, or serum and amino acids for 12 hr.
(H) NIH 3T3 cells treated with 250 nM Torin1 or deprived of serum, serum and glucose, or serum and amino acids for the indicated times were analyzed as in (D).
The mean eccentricity value for untreated cells is 0.633 (dashed line). Error bars indicate standard error for n = 3. * indicates p < 0.03; # indicates p < 0.01.
See also Figure S1.et al., 2010; Li et al., 2010; Porstmann et al., 2008). However, the
finding that rapamycin does not affect SREBP target gene
expression in all cellular contexts (Moule et al., 1995; Sharpe
and Brown, 2008) suggests that the mechanisms through
which mTORC1 regulates SREBP are complex and not yet fully
understood.
RESULTS
mTORC1, Nutrients, and Growth Factors Regulate
Nuclear Eccentricity
With the impetus that Torin1 causes greater mTORC1 inactiva-
tion than rapamycin, we looked for mTORC1-dependent pheno-types that might be largely resistant to rapamycin but sensitive to
Torin1. By visually inspecting NIH 3T3 cells treated with Torin1,
which as expected potently inhibits the phosphorylation at the
mTORC1-catalyzed sites on 4E-BP1 and S6K1 and T37/T46
and T389, respectively (Figure 1A), we observed that their nuclei,
including the nuclear matrix component lamin A, as well as DNA,
dramatically changed in their circumferential shapes (Figure 1B).
Rapamycin, although abolishing T389 S6K1 phosphorylation
(Figure 1A), lacked an effect on nuclear shape, and this corre-
lated with its inability to inhibit T37/T46 4E-BP1 phosphorylation
(Figures 1A and 1B). In geometric terms, it appeared that Torin1
increased nuclear eccentricity, a property that when referring to
circular objects is defined by the lengths of the major and minorCell 146, 408–420, August 5, 2011 ª2011 Elsevier Inc. 409
Figure 2. Lipin 1 Cytoplasmic-Nuclear Distribution Is Regulated by mTORC1, Growth Factors, and Nutrients
(A) NIH 3T3 cells overexpressing FLAG-lipin 1 were treated with 100 nM rapamycin, 250 nM Torin1, or vehicle for 8 hr. Cells were then processed in an
immunofluorescence assay to detect FLAG (green), costained with DAPI for DNA content (blue), and imaged.
(B) FLAG-lipin 1-overexpressing NIH 3T3 cells were treated with 250 nM Torin1 for the specified times and analyzed by immunoblotting for the phosphorylation
states and levels of the indicated proteins.
(C) Cells treated as in (B) were processed in an immunofluorescence assay to detect FLAG, costained with DAPI for DNA content, and imaged. The overlap of
FLAG immunoreactivity with DAPI staining was analyzed for >500 cells total. Error bars indicate standard error for n = 3.
(D) NIH 3T3 cells overexpressing FLAG-lipin 1 were grown in complete media or deprived of serum, serum and glucose, or serum and amino acids for 8 hr and
imaged as in (A).
See also Figure S2.axes, the apopasis (a) and periapsis (p), respectively (Figure 1C
and Figure S1A available online). Quantification of nuclei
treated with either of the mTOR inhibitors confirmed what
was visibly apparent (Figure 1B), that is, that Torin1 causes a
substantial increase in nuclear eccentricity compared with
rapamycin or vehicle treatment (Figure 1D). The effects of Torin1
are likely to be mTORC1 dependent as knockdown of the essen-
tial mTORC1 component, raptor, which positively regulates
mTORC1 signaling (Hara et al., 2002; Kim et al., 2002), increased
nuclear eccentricity, whereas depletion of themTORC1 pathway
negative regulator, TSC2, (Goncharova et al., 2002), decreased
nuclear eccentricity (Figures 1E and 1F). The effect of Torin1
on nuclear eccentricity was also mimicked by the dual PI3K/
mTOR inhibitor LY294002 but not by other agents that promote
a G1 arrest, such as a double thymidine block or inhibition of
MAPK signaling (Figures S1B and S1C), suggesting that nuclear
eccentricity is regulated in anmTORC1-dependentmanner inde-
pendently of cell-cycle progression.
Correlating with inhibition of 4E-BP1 phosphorylation (Fig-
ure 1G), combined serum and glucose deprivation increased
nuclear eccentricity similar to Torin1 or raptor knockdown
(Figures 1D and 1F) in a time-dependent manner (Figure 1H).
However, serum starvation alone, which partially inhibited 4E-
BP1 phosphorylation (Figure 1G), modestly increased nuclear
eccentricity (Figure 1H). These results suggest that nuclear
eccentricity is a cellular property that is dynamically regulated
by mTORC1 activity and environmental conditions.
mTORC1, Growth Factors, and Nutrients Regulate
Lipin 1 Localization
In investigating whether others have previously observed regula-
tion of nuclear eccentricity, we noted that the overexpression of410 Cell 146, 408–420, August 5, 2011 ª2011 Elsevier Inc.the Ned1 gene product in Schizosaccharomyces pombe
promotes this phenotype (Tange et al., 2002). This finding was
interesting to us because, previously, the mammalian Ned1
homolog, lipin 1, was shown to be phosphorylated in a nutrient-
and growth factor-stimulated, rapamycin-sensitive manner
(Huffman et al., 2002). However, at the time it was not known
whether lipin 1 regulated nuclear eccentricity, or what the func-
tion of the mTOR-dependent lipin 1 phosphorylation might be.
Because rapamycin lacks an effect on lipin 1 phosphatidic
acid phosphatase (PAP1) activity (Harris et al., 2007), we consid-
ered that mTOR might control some other aspect of lipin 1 func-
tion such as its localization. Strikingly, treatment of NIH 3T3 or
AML12 hepatocyte cells with Torin1 caused a complete redistri-
bution of recombinant lipin 1 from the cytoplasm to the nucleus
(Figure 2A and Figure S2A). Rapamycin, on the other hand,
largely lacked an effect on recombinant lipin 1 localization (Fig-
ure 2A and Figure S2A), and this correlated with a lack of effect
on 4E-BP1 phosphorylation (Figure 1A). That rapamycin lacked
an effect on lipin 1 localization is in disagreement with that
recently observed in 3T3-L1 adipocytes (Pe´terfy et al., 2010).
However, as the completeness of inhibition of rapamycin on
mTORC1 signaling varies considerably between cell types
(Choo et al., 2008), we reasoned that this discrepancy on lipin
1 localization might be explained by the differing rapamycin
sensitivities of mTORC1 in the cell types assessed. In support
of this, in HEK293T cells, unlike in NIH 3T3 cells (Figure 1A and
Figure 2A), lipin 1 nuclear translocation and S65 4E-BP1 phos-
phorylation were partially sensitive to rapamycin (Figures S2B
and S2C). Aswith recombinant lipin 1, Torin1 or combined serum
and amino acid or glucose deprivation, but not rapamycin,
caused strong nuclear relocalization of endogenous lipin 1
(Figure S2D).
It was possible that the effects of Torin1 on lipin 1 nuclear
translocation might require inhibition of mTORC2/PI3K concom-
itantly with or independently of inhibiting mTORC1 (Jacinto
et al., 2004; Peterson et al., 2009; Sarbassov et al., 2004;
Thoreen et al., 2009). To address this, we monitored the time
dependence of Torin1 treatment on lipin 1 localization. After
acute treatment (1 hr), correlating with the downregulation of
mTORC1 as well as mTORC2/PI3K signaling, as judged by
T308 Akt phosphorylation at this early time point, lipin 1 partially
accumulated in the nucleus (Figures 2B and 2C). However,
at later times (R3 hr), despite mTORC2/PI3K activity being
restored, lipin 1 was fully retained in the nucleus, and this corre-
lated with the maintained impairment of mTORC1 signaling
(Figures 2B and 2C). Torin1 also caused lipin 1 nuclear transloca-
tion to the same extent in rictor-deficient cells as in those con-
taining intact mTORC2 (Figure S2E), which together with the
above results suggests that lipin 1 cytoplasmic-nuclear relocali-
zation responds to mTORC1 and not mTORC2 status.
Unlike serum deprivation alone, serum deprivation combined
with glucose or amino acid deprivation promoted the full
nuclear accumulation of lipin 1 (Figure 2D and Figure S2D).
Similarly, in HEK293T cells, amino acid deprivation caused
complete lipin 1 nuclear accumulation (Figure S2F). LY294002
or the AMPK-activating compound AICAR, which strongly impair
mTORC1 signaling, also promoted complete lipin 1 nuclear
translocation (Figure S2G). Lastly, because the phosphorylation
states of lipin 1, lipin 2, and Pah1/Smp2 are regulated by cell-
cycle activity (Grimsey et al., 2008; O’Hara et al., 2006), we
tested whether various cell-cycle perturbations affect lipin 1
localization. However, neither G1 arrest by a double thymidine
block, CDK inhibition, nor MAPK inhibition affected lipin 1
localization (Figure S2G). Taken together, these results suggest
that lipin 1 cytoplasmic retention is positively promoted by
mTORC1.
mTORC1 Directly Phosphorylates Lipin 1 to Regulate
Lipin 1 Localization and Nuclear Eccentricity
We sought to gain insight into the mechanisms through which
mTORC1 regulates lipin 1 translocation. Because mTORC1 is
a protein kinase, we focused on the lipin 1 phosphorylation
state and the 19 phosphorylation sites previously identified on
it (Harris et al., 2007). In our mass spectrometry analysis, we
detected 17 of the 19 published sites as well as 2 novel sites,
S237 and T335. Nine of the sites fall within ‘‘proline-directed’’
motifs (S/T-P) (Figure 3A) like those in 4E-BP1 that are directly
phosphorylated by mTOR (Brunn et al., 1997; Burnett et al.,
1998; Gingras et al., 1999). We raised antibodies to 2 of
the proline-directed sites, S106 and S472, and confirmed
their phosphospecificities using a form of lipin 1 in which we
mutated the serine and threonine residues to alanines at 17 of
the 19 sites, including S106 and S472 (hereafter referred to as
‘‘17xS/T/ A lipin 1’’) (Figure S3A). Rapamycin mostly inhibited
and Torin1 completely inhibited S106 lipin 1 phosphorylation,
which is a pattern similar to the effect of these inhibitors on
S65 4E-BP1 phosphorylation (Figure 3B, Figure S3B). On the
contrary, S472 lipin 1 phosphorylation, like T37/T46 4E-BP1
phosphorylation, was largely insensitive to rapamycin but sensi-
tive to Torin 1 (Figure 3B, Figure S3B). Interestingly, a prolongedcourse (12 hr) of Torin1, but not rapamycin, impaired S237 and
S472 lipin 1 phosphorylation (Figure S3C). Also comparable
to 4E-BP1 phosphorylation, combined serum and nutrient
deprivation strongly downregulated lipin 1 S106 and S472 phos-
phorylation, whereas serum deprivation alone only partially
inhibited lipin 1 phosphorylation at these same sites (Figure 3C).
Therefore, similar to the effect of mTORC1 on the 4E-BP1 phos-
phorylation state, nuclear eccentricity, and lipin 1 localization,
mTORC1 activity regulates lipin 1 multisite phosphorylation in
a graded manner.
Whereas T389 S6K1 can be efficiently phosphorylated in vitro
by mTOR in the absence of raptor, T37/T46 4E-BP1 phosphory-
lation requires raptor (Hara et al., 2002; Yip et al., 2010). Because
lipin 1 phosphorylation was similar to 4E-BP1 phosphorylation in
terms of its rapamycin and Torin1 sensitivities (Figure 3B), we
sought to determine whether lipin 1 can be directly phosphory-
lated at S106 and S472 in an mTORC1-dependent manner
and whether mTOR might also require raptor to phosphorylate
lipin 1. To test this, we isolated mTOR via the mTORC1 compo-
nent, mLST8/GbL (Kim et al., 2003), from control or raptor
knockdown cells and performed in vitro kinase assays on puri-
fied lipin 1. An mTORC1-containing mLST8/GbL purification,
but not one where raptor was depleted in cells by RNAi and/or
inhibited with Torin1, readily phosphorylated S106 and S472 lipin
1 and T37/T46 4E-BP1 (Figure 3D and Figure S3D). We observed
similar results on S106 lipin 1 using mTORC1 highly purified via
gel filtration (Yip et al., 2010) (Figure S3E). Importantly, wild-
type lipin 1 was highly phosphorylated by mTORC1 (compare
with the mTORC1 substrate S6K1), whereas mutation of its 17
sites virtually abolished the ability of mTORC1 to phosphorylate
it (Figure S3F). Lastly, as multiple TORC1 substrates remain
bound to TORC1 when purified from cells (Lempia¨inen et al.,
2009; Schalm et al., 2003), we assessed lipin 1 for this behavior.
Indeed, raptor and coexpressed raptor and mTOR copurified
with lipin 1 but not with the metap2 or rap2a control proteins
(Figure S3G). That lipin 1 did not interact with mTOR alone and
that mTOR did not increase the abundance of raptor copurifying
with lipin 1 suggest that lipin 1 interacts with mTORC1 via raptor.
Taken together, the above data suggest that mTORC1 is a bona
fide lipin 1 kinase.
BecausemTORC1 kinase activity regulates lipin 1 localization,
we reasoned that a mechanism through which lipin 1 localization
might be regulated is by its phosphorylation at mTORC1-cata-
lyzed sites. Mutation of only the rapamycin-sensitive-catalyzed
site, S106, to alanine did not affect the lipin 1 cytoplasmic-
nuclear distribution (Figure 3E). Whereas, mutating 6 of the 19
lipin 1 sites (2 of the 7 proline-directed sites) caused partial lipin 1
redistribution (Figure 3E). Lastly, mutation of all 17 lipin 1 sites to
alanine, including S106 and S472, was sufficient to promote the
full lipin 1 nuclear accumulation (Figure 3E and Figure S3H).
Therefore, inactivation of mTORC1 leads to nuclear lipin 1
sequestration by a mechanism that requires its dephosphoryla-
tion at numerous mTORC1-regulated sites.
As the 17xS/T/ A mutant lipin 1 recapitulated the effects of
mTORC1 inactivation on lipin 1 localization, we determined
whether lipin 1 might regulate the effects of mTORC1 on
nuclear eccentricity. Indeed, the time-dependent increases in
nuclear eccentricity caused by Torin1 in cells containing lipin 1Cell 146, 408–420, August 5, 2011 ª2011 Elsevier Inc. 411
Figure 3. mTORC1-Catalyzed Lipin 1 Phosphorylation Regulates Lipin 1 Localization and Nuclear Eccentricity
(A) Schematic of the location of lipin 1 phosphorylation sites. NLIP, N-terminal lipin 1 conserved region. CLIP, C-terminal lipin 1 conserved region. NLS, nuclear
localization signal (in red). Capitalized serine or threonine residues (in red) indicate the lipin 1 phosphorylation sites that are followed in the +1 position by a proline
residue.
(B) NIH 3T3 cells transfected with FLAG-lipin 1 were treated with 100 nM rapamycin, 250 nM Torin1, or vehicle for 4 hr. FLAG immunoprecipitates and cell lysates
were analyzed by immunoblotting for the phosphorylation states and levels of the specified proteins.
(C) NIH 3T3 cells transfected with FLAG-lipin 1 were grown in complete media or deprived of serum, serum and glucose, or serum and amino acids for 4 hr.
(D) HEK293T cells overexpressing FLAG-mLST8/GbLwere infected with lentivirus expressing an shRNA targeting raptor or GFP. FLAG immunoprecipitates were
analyzed for mTOR kinase activity toward lipin 1 in the presence of 250 nM Torin1 or vehicle.
(E) FLAG-wild-type, 1xS/T/ A, 6xS/T/ A, and 17xS/T/ A lipin 1-overexpressing NIH 3T3 cells were processed in an immunofluorescence assay to detect
FLAG and imaged.
(F) Indicated FLAG-tagged lentiviral expression vectors were stably introduced into fld cells and RNA was isolated 5 days post-infection. All mRNAs were
measured by qRT-PCR and normalized to 36B4 mRNA levels. Error bars indicate standard error for n = 4.
(G) Each lipin 1-expressing cell line generated as in (F) was processed in an immunofluorescence assay to detect lamin A and imaged.
(H) Images processed in (G) were analyzed for nuclear eccentricity as in Figure 1D. Mean eccentricity values for three independent fields for each condition
(>500 cells total) are as follows: catalytic dead, wild-type lipin 1 (gray) 0.666; catalytic dead, 17xS/T/ A lipin 1 (gray hatched line) 0.671; catalytically active, wild-
type lipin 1 (black) 6.76; catalytically active, 17xS/T/ A lipin 1 (red) 0.713.
See also Figure S3.were absent in lipin 1-deficient (fld, fatty liver dystrophy) cells
(Pe´terfy et al., 2001) (Figure S3I). We next stably expressed
either the catalytically active or inactive forms of the wild-type
(cytoplasmic) or the 17xS/T/ A mutant (nuclear) lipin 1 in fld
cells. While mutation of the 17 phosphorylation sites on lipin 1
did not affect PAP1 activity (Figure S3J), nor did lipin 1 catalytic
activity affect its localization (Figure S3K), the expression of the
catalytically active, nuclear-localized 17xS/T/ A mutant lipin
1, but not its catalytic dead or the wild-type form, was sufficient
to increase nuclear eccentricity (Figures 3F– 3H). These results
suggest that the effects of mTORC1 on nuclear eccentricity are
driven, at least in part, by the catalytic activity of nuclear-local-
ized lipin 1.412 Cell 146, 408–420, August 5, 2011 ª2011 Elsevier Inc.Repression of SREBP-Dependent Transcription
by Constitutively Dephosphorylated
and Nuclear-Localized Lipin 1
Because lipin 1 regulates lipid homeostasis (Finck et al., 2006;
Han et al., 2006; Rehnmark et al., 1998), we were interested in
whether nuclear-localized lipin 1 might contribute to the regula-
tion by mTORC1 of lipid biosynthetic gene expression. The
SREBP pathway was an attractive transcriptional pathway to
investigate because the cell-type-specific effects of rapamycin
on lipin 1 localization (Figure 2B and Figure S2B) were reminis-
cent of those on SREBP target gene expression (Du¨vel et al.,
2010; Moule et al., 1995; Porstmann et al., 2008; Sharpe and
Brown, 2008).
Figure 4. mTORC1-Regulated Lipin 1 Relocalization Is Necessary and Sufficient to Repress SREBP-Dependent Transcription
(A) NIH 3T3 cells were treated with 100 nM rapamycin, 250 nM Torin1, or vehicle for the indicated times. All mRNAs were measured by qRT-PCR and normalized
to 36B4 mRNA levels. Error bars indicate standard error for n = 4. * indicates p < 0.04; # indicates p < 0.02.
(B) NIH 3T3 cells were grown in complete media, deprived of serum, serum and glucose, or serum and amino acids for 12 hr. All mRNAs were analyzed as in (A).
Error bars indicate standard error for n = 4. * indicates p < 0.02; # indicates p < 0.03.
(C) Wild-type or fld MEFs were treated with 250 nM Torin1 or vehicle for the indicated times. All mRNAs were measured by qRT-PCR and normalized to 36B4
mRNA levels. * indicates p < 0.02.
(D) Wild-type or fld MEFs were deprived of serum or serum and amino acids for 8 hr. All mRNAs were analyzed as in (C). * indicates p < 0.01.
(E) Indicated FLAG-tagged lentiviral expression vectors were stably introduced into fld cells and RNA was isolated 5 days post-infection. All mRNAs were
analyzed as in (A). * indicates p < 0.007.
(F) HepG2 cells were cotransfectedwith expression constructs containing a transcriptionally active, truncated form of SREBP-1 alongwith a construct containing
a SREBP-1-responsive promoter of either the FASN or SCD1 genes tethered to luciferase cDNA and treated with 20 nM rapamycin, 250 nM Torin1, or vehicle for
4 hr. Luciferase measurements for each promoter activity reporter were normalized to those of SREBP-1-transfected, vehicle-treated cells. * indicates p < 0.001;
# indicates p < 0.01.
(G) HepG2 cells cotransfected as in (F) were additionally transfected with empty vector, wild-type lipin 1, or 17xS/T/ A lipin 1. * indicates p < 0.0001; # indicates
p < 0.02.
See also Figure S4.We first determined to what extent rapamycin and Torin1
regulated the mRNA expression of numerous genes that are
known to be induced by SREBP-1 and/or SREBP-2, such as fatty
acid synthase (FASN), acetyl-CoA carboxylase alpha (ACACA),
stearoylCoA-desaturase (SCD1),HMG-CoAreductase (HMGCR),
and farnesyl diphosphate synthase (FDPS) (Horton et al., 2003).In a time-dependent manner, Torin1 strongly downregulated all
SREBP targets we examined, yet rapamycin was largely ineffec-
tive at decreasing the expression of these same targets at the
latest time point (Figure 4A). Neither Torin1 nor rapamycin
decreased SREBP-1 mRNA, whereas both inhibitors downregu-
lated SREBP-2 mRNA to a comparable extent (Figure S4A).Cell 146, 408–420, August 5, 2011 ª2011 Elsevier Inc. 413
Similar to the effects of Torin1, serum and glucose or amino
acid deprivation strongly downregulated SREBP target gene
expression compared with cells grown in complete media
or deprived only of serum (Figure 4B). Correlating with the differ-
ential strengths of these mTORC1-regulating inputs on lipin 1
localization, these results suggest that the redistribution of cyto-
plasmic lipin 1 to the nucleusmight be important in the regulation
of SREBP target gene expression by mTORC1. To test this, we
monitored SREBP target mRNA levels in the presence or
absence of Torin1 in wild-type and fld cells. At time points after
which Torin1 caused lipin 1 to fully enter the nucleus (Figure 2C),
fld cells were completely refractory to the effects of Torin1 on
SREBP target expression (Figure 4C) without differentially regu-
lating SREBP-1 mRNA levels (Figure S4B). Complementary to
these findings, lipin 1 deficiency prevented the reduction in
SREBP target gene expression caused by amino acid depriva-
tion (Figure 4D).
We measured SREBP target gene expression in fld cells in
which we stably expressed either the wild-type or the constitu-
tively dephosphorylated, nuclear-localized 17xS/T/ A mutant
lipin 1. Whereas wild-type lipin 1 had little or no effect on SREBP
target mRNA levels, the 17xS/T/ A lipin 1 mutant repressed, in
a manner dependent on its catalytic activity, all SREBP targets
examined (Figure 4E). Because it is possible that mTORC1 and
lipin 1 might control SREBP target mRNA levels independently
of SREBP itself, we measured the effects of mTORC1 and lipin
1 on FASN and SCD1 promoter activities driven by a truncated,
nuclear-localized, transcriptionally active form of SREBP-1
(Shimano et al., 1996). Fitting with the effects of Torin1 and rapa-
mycin on endogenous FASN and SCD1 mRNA expression
(Figure 4A), Torin1 strongly impaired SREBP-1-induced, FASN
and SCD1 promoter activities, yet rapamycin more modestly
impaired the activities of these same reporters (Figure 4F and
Figure S4C). Similarly, 17xS/T/ A lipin 1, unlike wild-type lipin
1, potently downregulated both FASN and SCD1 promoter activ-
ities (Figure 4G). These results establish lipin 1 as both necessary
and sufficient for mediating the effects of mTORC1 inhibition on
SREBP transcriptional activity.
mTORC1-Dependent Regulation of Nuclear SREBP
Protein Abundance Is Mediated by Lipin 1
Because mTORC1 promotes the expression of the mature,
nuclear (Du¨vel et al., 2010; Porstmann et al., 2008), as well as
a truncated, constitutively active form of the SREBP-1 protein
(Figure S4C), we asked whether lipin 1 might regulate the effects
of mTORC1 on nuclear SREBP protein levels. In nuclear extracts
from Torin1-treated cells, SREBP protein levels were largely
ablated after only 4 hr of treatment and were maintained at
very low levels up to 12 hr (Figure 5A). On the contrary, rapamy-
cin only weakly reduced nuclear SREBP protein levels at all time
points tested, and neither inhibitor downregulated cytoplasmic
SREBP-1 levels (Figure 5A). Knockdown of SREBP-1 in multiple
cell types strongly downregulated both SREBP target gene
expression as well as SREBP-2 mRNA expression (Du¨vel et al.,
2010) (Figures S5A and S5B) suggesting that the reduction in
cytoplasmic SREBP-2 protein levels caused by mTORC1 inhibi-
tion (Figure 5A) could be due to mTORC1-dependent regulation
of SREBP-1 on SREBP-2 mRNA levels. Nuclear SREBP protein414 Cell 146, 408–420, August 5, 2011 ª2011 Elsevier Inc.levels were also strongly downregulated by combined serum
and glucose or amino acid deprivation in comparison to cells
given complete media or deprived only of serum (Figure 5B).
Confirming the generality of these findings, in HEK293T cells,
Torin1 or amino acid starvation strongly reduced nuclear SREBP
protein expression (Figures S5C and S5D). To test a role for
lipin 1 in mediating the effects of mTORC1 on nuclear SREBP
protein, we assessed nuclear SREBP levels in wild-type and
lipin 1-deficient cells after Torin1 treatment. In contrast to lipin
1-containing cells, fld cells were highly resistant to the effects
of Torin1 on nuclear SREBP protein levels (Figure 5C). To assess
whether mTORC1-controlled localization of lipin 1 is critical to
these effects, wemeasured nuclear SREBP protein levels in cells
expressing the wild-type or the 17xS/T/ A mutant lipin 1. The
17xS/T/ A mutant, but not wild-type lipin 1 or the control
protein, metap2, repressed nuclear SREBP protein expression
in multiple cell types (Figure 5D, Figures S5E and S5F). Taken
together, these results establish the constitutively dephosphory-
lated, nuclear form of lipin 1 as both necessary and sufficient for
mediating the effects of mTORC1 inhibition on the expression of
nuclear SREBP proteins.
A growing body of work suggests that A-type lamins colocal-
ize with transcriptional regulators (Johnson et al., 2004; Wilson
and Foisner, 2010). However, less is known about how the
localizations of these transcription factors are regulated.
Because mTORC1-dependent changes in lipin 1 localization
strongly altered the structure of the lamin A-containing nuclear
matrix and because lamin A is known to bind SREBP (Lloyd
et al., 2002), we considered whether the localization of SREBP
might be important in the mTORC1- and lipin 1-dependent regu-
lation of its nuclear depletion. In untreated cells, full-length
SREBP-1 and SREBP-2 appeared diffusely localized throughout
the cell, in agreement with a previous report (Figure 5E and Fig-
ure S5F) (Wang et al., 1994). Strikingly, in the presence of
Torin1, SREBP-1 and SREBP-2 decreased in overall immunos-
taining intensity, consistent with our fractionation studies (Fig-
ure 5A and Figure S5C), but became concomitantly enriched
at the nuclear periphery (Figure 5E and Figure S5G) and partially
colocalized with lamin A (Figure 5E). Expression of the constitu-
tively nuclear 17xS/T/ A lipin 1 (Figure S5H), in contrast to
wild-type lipin 1, also caused marked turnover of nuclear
SREBP-1 that was associated with residual SREBP-1 partially
colocalizing with lamin A (Figure 5F and Figure S5H). Interest-
ingly, these mTORC1- and lipin 1-regulated changes in SREBP
immunostaining are similar to those seen in cells expressing
lipodystrophy-causing lamin Amutations or treated with lipodys-
trophy-inducing medications that alter lamin A distribution
(Capanni et al., 2005; Caron et al., 2003). Thus, mTORC1- and
lipin 1-dependent changes in SREBP nuclear abundance corre-
late with its redistribution into proximity to lamin A at the nuclear
periphery.
Lipin 1 Is Required for the Effects of mTORC1 on the
SREBP Pathway and Lipid Homeostasis in Mice
To test a role for mTORC1 and lipin 1 in the regulation of the
SREBP pathway in a physiologically meaningful context, we
deleted raptor in the postnatal liver in floxed raptor mice by
expressing Cre recombinase under the control of the Albumin
Figure 5. Constitutively Dephosphorylated, Nuclear Lipin 1 Decreases Nuclear SREBP Protein Abundance
(A) NIH 3T3 cells were treated with 20 nM rapamycin, 250 nM Torin1, or vehicle for the indicated times, cytoplasmic and nuclear fractions were isolated, and the
levels of the indicated proteins were analyzed by immunoblotting.
(B) NIH 3T3 cells were grown in complete media or deprived of serum, serum and glucose, or serum and amino acids for 4 hr and analyzed as in (A).
(C) Wild-type or fld MEFs were treated with 250 nM Torin1 or vehicle for the indicated times and analyzed as in (A).
(D) Indicated FLAG-tagged lentiviral expression vectors were stably introduced into NIH 3T3 cells and analyzed as in (A).
(E) NIH 3T3 cells overexpressing FLAG-SREBP-1 were treated with 250 nM Torin1 or vehicle for 8 hr. Cells were then processed in an immunofluorescence assay
to detect FLAG (red) and lamin A (green), costained with DAPI for DNA content (blue), and imaged.
(F) Fld cells coexpressing HA-SREBP-1 and wild-type or 17xS/T/Amutant lipin 1 were processed in an immunofluorescence assay to detect HA (red) and lamin
A (green), costained with DAPI for DNA content (blue), and imaged.
See also Figure S5.promoter (Sengupta et al., 2010). We first confirmed that S106
and S472 lipin 1 phosphorylation are regulated by mTORC1-
regulating inputs in hepatocytes and that raptor expression,
mTORC1, and PI3K/Akt signaling were altered specifically in
the livers of albumin-CRE+; floxed raptor mice (Li-RapKO) (Fig-
ures S6A and S6B, Figure 6A). Surprisingly, despite strongly
perturbing mTORC1/PI3K signaling in their livers, Li-RapKO
mice developed normally and at 4months of age were of compa-
rable body weight as wild-type, control (Ctrl) mice (Figure S6C).
Therefore, we challenged the wild-type and Li-RapKO mice with
a high-fat and high-cholesterol ‘‘Western’’ diet. The effects of
raptor loss were now clear: unlike with chow-feeding, where
both groups gained weight at a similar rate, Western diet-fed
Li-RapKO mice gained substantially less weight than wild-type
animals despite similar food intake (Figures S6C and S6D). The
fasted livers of Western diet but not chow-fed Li-RapKO micewere also substantially reduced in size and were less yellowish
in appearance and disorganized by intracellular droplets com-
pared with the fasted livers of control mice (Figure 6B). We
next measured SREBP target gene expression in chow- and
Western diet-fed wild-type and Li-RapKO mice. As expected,
the expression of FASN and HMGCR were repressed by raptor
loss, though the degree of inhibition was substantially greater
on theWestern diet, particularly for FASN (Figure 6C). The eleva-
tions in liver triglycerides and plasma cholesterol in wild-type
animals on the Western compared with the chow diet were
also largely blocked by raptor loss (Figure 6D), results that,
notably, phenocopy those seen in SREBP-1c knockout mice
(Kalaany et al., 2005).
We suspected that lipin 1 would be important in the resistance
of Li-RapKO animals to some of the phenotypic consequences
caused by the Western diet because fld fibroblasts wereCell 146, 408–420, August 5, 2011 ª2011 Elsevier Inc. 415
Figure 6. Response of Liver-Specific Raptor Knockout Mice to a High-Fat and High-Cholesterol (Western) Diet Is Lipin 1 Dependent
(A) Control (floxed raptor; Albumin-CRE, abbreviated Ctrl) and Li-RapKO (floxed raptor; Albumin-CRE+) were starved of chow overnight and refed for 45 min.
Liver and muscle tissue lysates were prepared and analyzed by immunoblotting for the phosphorylation states and levels of specified proteins.
(B) Representative 13 or 203 images of control and Li-RapKO livers taken from chow and Western diet-fed mice.
(C) Liver tissue was isolated and RNA was extracted from the indicated mice fed their respective diets for 6–8 weeks. All mice were starved for 4 hr prior to
liver harvesting. All mRNAs were measured by qRT-PCR and normalized to 36B4 mRNA levels. Error bars indicate standard error for n = 4–6. C, chow,
W, Western. * indicates p < 0.02, #p < 0.04, ^p < 0.05.
(D) Liver tissue from which lipids were extracted and plasma for cholesterol measurements were obtained from mice fed the indicated diets for 6–8 weeks
and starved 4 hr prior to sample harvesting. Error bars indicate standard error for n = 4 (liver triglycerides), n = 6 (plasma cholesterol). * indicates p < 0.004,
# indicates p < 0.05.
(E) Western diet-fed control and Li-RapKO were infected with adenovirus-expressing shRNAs targeting lacZ or lipin 1. Liver was harvested 5 days after infection
and lysates prepared, and immunoblotting was performed for the indicated proteins.
(F) mRNA was isolated and analyzed as in (C). * indicates p < 0.01, # indicates p < 0.05 in comparing LacZ shRNA versus lipin 1 shRNA-treated Li-RapKO mice.
(G) Liver triglycerides and plasma cholesterol were measured as in (D). * indicates p < 0.05, # indicates p < 0.05.
See also Figure S6.resistant to the effects of Torin1 on SREBP target gene expres-
sion (Figure 4C). Indeed, using two distinct adenovirally delivered
shRNAs to lipin 1, we depleted lipin 1 from the livers of Western
diet-fed Li-RapKO mice (Figure 6E), and this largely restored
SREBP target gene expression to the levels seen in control
mice (Figure 6F). Correspondingly, the levels of liver triglycerides
and plasma cholesterol in Western diet-fed Li-RapKO mice were
also re-elevated after the lipin 1 knockdown to those in control
mice (Figure 6G). Therefore, the SREBP pathway in the liver is
positively regulated by mTORC1 in a manner that is opposed
by lipin 1, and this regulation is critical for the development of416 Cell 146, 408–420, August 5, 2011 ª2011 Elsevier Inc.hepatic steatosis and hypercholesterolemia caused by pro-
longed high-fat and high-cholesterol feeding.
DISCUSSION
Our findings provide insight into howmTORC1 regulates SREBP
transcriptional activity and are consistent with a model in which
loss of mTORC1-mediated lipin 1 phosphorylation promotes its
nuclear entry and promotes the downregulation of nuclear
SREBP protein (Figure 7). This model suggests several inter-
esting avenues for future exploration. Regarding the role of
Figure 7. Model of mTORC1/Lipin 1-Dependent Regulation of
SREBP Transcriptional ActivitymTORC1 in regulating lipin 1 phosphorylation-dependent
changes in its localization, it will be interesting to determine the
relative rapamycin sensitivities of each lipin 1 phosphorylation
site. As S472 lipin 1 phosphorylation appears to be partially
rapamycin sensitive (Figure 3B), it is possible that this and the
other sites we have characterized do not represent the key
rapamycin-resistant site(s) modified by mTORC1 during multi-
site lipin 1 phosphorylation. However, that multiple lipin 1 sites
are at least partially rapamycin resistant (Figure 3B, Figures
S3B and S3C) and that mutation of six lipin 1 phosphorylation
sites causes partial lipin 1 nuclear translocation (Figure 3E)
suggest an alternative conclusion to a strict hierarchical phos-
phorylation model. That is, perhaps the differential effects of ra-
pamycin versus Torin1 on lipin 1 function reflect the additive
effect of more extensive dephosphorylation of lipin 1 by Torin1
at each of themultiple sites targeted bymTORC1. It also remains
unknown how mTORC1/lipin 1 regulates SREBP nuclear protein
levels. Interestingly, with mTORC1 inactivation or expression of
nuclear-localized lipin 1, we often observed residual SREBP in
proximity to lamin A as aggregates (Figures 6D and 6E, Fig-
ure S6G) whose morphology and localization resembled lyso-
somes (Yu et al., 2010). AsmTORC1 is known to regulate nuclear
SREBP levels independently of the proteasome (Du¨vel et al.,
2010), it will be interesting in the future to explore whether a lyso-
some-requiring autophagic process is involved in the mTORC1-
and lipin 1-regulated turnover of nuclear SREBP.
It was interesting that mTORC1- and lipin 1-dependent
changes in nuclear eccentricity correlated with their effects on
SREBP transcriptional activity because one of the structural
components of the nuclear matrix, lamin A, has several estab-
lished connections with the SREBP pathway: (1) lamin A physi-
cally interacts with SREBP-1 and SREBP-2, and its overexpres-
sion downregulates the mRNA expression of the adipogenic
SREBP target, PPARg2 (Boguslavsky et al., 2006; Lloyd et al.,
2002); (2) lamin A mutations in humans commonly result in a lip-
odystrophy, a condition characterized by abnormal adipose
tissue that is also seen in adipocyte-specific SREBP-1-overex-pressing mice (Capell and Collins, 2006; Shimomura et al.,
1999). As we failed to detect a physical interaction between lipin
1 and SREBP-1 (data not shown), in the future it will be exciting to
test whether lipin 1 might regulate nuclear SREBP protein via
a more indirect mechanism, such as through its effects on the
nuclear lamina.
Because mTORC1 promotes lipogenesis and inhibits glucose
uptake (Du¨vel et al., 2010; Jiang et al., 2008; Porstmann et al.,
2008), it is curious that rapamycin is known to cause numerous
features of the metabolic syndrome: hyperlipidemia, hypercho-
lesterolemia, and insulin resistance in humans and in mice
(Blum, 2002; Cunningham et al., 2007). Considering the discrep-
ancies we find between the effects of rapamycin and Torin1 in
regulating lipin 1 and SREBP, it is clear that further examination
of the differential strengths of various mTORC1 inhibitors on
cellular and organismal lipid and glucose homeostasis is
required. Through such work, it should be possible to determine
whether potent mTORC1-inhibiting drugs could be useful as
potential treatments for metabolic syndrome.
EXPERIMENTAL PROCEDURES
Materials
Reagents were obtained from the following sources: antibodies to mTOR,
lamin A or lamin A/C (sc-20680, sc-6215), and SREBP-1 (sc-13551) from
Santa Cruz Biotechnology; rabbit polyclonal and monoclonal antibodies to
phospho-S106 lipin 1, phospho-S472 lipin 1, phospho-T389 S6K1 (cat.#
9234), phospho-T37/T46 4E-BP1 (cat.# 2855, T36/T45 forM.musculus), phos-
pho-S65 4E-BP1 (cat.# 9451), and T308 Akt (cat.# 2965) from Cell Signaling
Technology; rabbit polyclonal antibody to SREBP-2 from Abcam (ab30682);
antibodies to lipin 1 were previously described (Huffman et al., 2002). GST-
4E-BP1 was previously described (Burnett et al., 1998). Torin1 was previously
described (Liu et al., 2010; Thoreen et al., 2009) and was kindly provided by
Nathaniel Gray (Harvard Medical School).
Nuclear Eccentricity and Lipin 1 Nuclear-Cytoplasmic Proportion
Measurements
Nuclear eccentricity was measured with CellProfiler (http://www.cellprofiler.
org) using 103 images with the eccentricity measurement being made on
nuclei identified by lamin A immunostaining. FLAG-lipin 1 nuclear proportion
was also quantified by CellProfiler as follows: after illumination correction,
the nuclei were automatically identified using the DAPI staining; the cyto-
plasmic compartment was defined by expanding the edges of the nuclei
20 pixels in every direction; nuclear proportion was then measured as
nuclear intensity/(nuclear+cytoplasmic intensity). Further mTORC1/SREBP/
lipin 1/lamin A analysis can be found at http://www.onarbor.com.
Immunofluoresence Assays
25,000–100,000 cells were plated on fibronectin-coated glass coverslips,
fixed with 4% paraformaldehyde, and permeabilized with 0.2% Triton X-100.
Permeabilized cells were blocked in 0.25% BSA PBS, incubated with primary
antibody (FLAG, HA, and/or lamin A sc-20680) in blocking buffer overnight at
4C (for detection of lipin 1 and/or lamin A) or 2 hr at room temperature (for
detection of SREBP-1 or SREBP-2 and lamin A or lipin 1), and subsequently
incubated with secondary antibodies (diluted in blocking buffer 1:1000) for
1 hr at room temperature. 2–43 PBS washes were used in between all
preceding steps. The coverslips were mounted on glass slides using Vecta-
shield containing DAPI (Vector Laboratories) and imaged with a 103 or 633
objective by using epifluorescence microscopy.
Gene Expression Analysis
Total RNA was isolated and reverse-transcription was performed from
cells grown in the indicated conditions. The resulting cDNA was diluted inCell 146, 408–420, August 5, 2011 ª2011 Elsevier Inc. 417
DNase-free water (1:20) followed by quantification by real-time PCR. mRNA
transcript levels were measured using Applied Biosystems 7900HT Sequence
Detection System v2.3 software. All data are expressed as the ratio between
the expression of target gene to the housekeeping genes 36B4 and/or
GAPDH. Each treated sample was normalized to the level of the vehicle
controls of the same cell type.
Cytoplasmic-Nuclear Fractionation
For nuclear SREBP fractionation studies, protease pellets were added to NE-
PER buffers (Thermo Fischer Scientific) and nuclear extracts were prepared
according to the manufacturer’s protocol. Whole-cell lysates were prepared
by mixing matched cytoplasmic fractions and nuclear fractions.
Determination of Liver Triglycerides
Liver sections (25–50 mg) were homogenized in 900 ml of a 2/1 chloroform/
methanol mixture. The homogenate was combined with 300 ml of methanol,
vortexed, and centrifuged for 15 min at 3,000 rpm. 412.5 ml of supernatant
was transferred to a new glass tube, 200 ml of chloroform and 137.5 ml of
0.73% NaCl was added, and the resulting mixture was vortexed for 30 s and
centrifuged at 5,000 rpm for 3 min. The upper phase was discarded and
400 ml of a 3/48/47 mixture of chloroform/methanol/NaCl (0.58%) was added
towash the lower phase andwas centrifuged at 5,000 rpm for 3min. After three
washes, the lower phase was evaporated and resuspended in 1 ml of isopro-
panol. Triglyceride levels were determined with a standard assay kit (Infinity
Triglycerides Reagent TR22421) from Thermo Scientific according to the
manufacturer’s instructions. Liver triglycerides were normalized by liver
section weight.
Determination of Plasma Cholesterol Content
Mouse plasma was obtained from tail vein blood, chelated with EDTA, and
centrifuged at 5,000 rpm for 10min to remove red blood cells. Levels of plasma
cholesterol were determined using a standard assay kit (Infinity Cholesterol
Reagent TR13421) from Thermo Scientific according to manufacturer’s
instructions.SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures and
six figures and can be found with this article online at doi:10.1016/j.cell.
2011.06.034.
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